| Literature DB >> 36262466 |
Vito Anggarino Damay1, Setiawan Setiawan2, Ronny Lesmana2, Mohammad Rizki Akbar3, Antonia Anna Lukito1.
Abstract
The popularity of the electronic cigarette has soared in the last decades. However, the health effect of smoking electronic cigarettes on the vascular system is unclear. This systematic review examines the electronic cigarettes' effect on the vascular system from recent evidence. A systematic search was conducted in MEDLINE (PubMed) database from January 2016 to August 2021 for studies assessing the vascular effect of chronic use of electronic cigarettes on human and animal. The Cochrane Risk of Bias 2, NIH Quality Assessment for Cross-Sectional Study, and SYRCLE's Risk of Bias were used to assess the risk of bias in interventional, observational, and animal study, respectively. A narrative synthesis of evidence is provided to describe results. From 101 retrieved studies related to electronic cigarettes effect on the vascular system, a total of 16 studies are included in this review. The overall results indicated that electronic cigarette use is associated with adverse events in the vascular, including the incident of elevated oxidative stress, endothelial dysfunction, inflammation, arterial stiffness, and the development of atherosclerotic lesion. Further studies should broaden perspectives and reveal more about the mechanism of how electronic cigarettes impact on vascular system.Entities:
Year: 2022 PMID: 36262466 PMCID: PMC9553677 DOI: 10.1155/2022/3216580
Source DB: PubMed Journal: J Smok Cessat ISSN: 1834-2612
Figure 1PRISMA Flow Diagram of study selection.
Characteristics of included study.
| # | Reference | Sample | Control group | Nicotine | Length of exposure | Overall risk of bias/quality∗ | Result | |
|---|---|---|---|---|---|---|---|---|
| Characteristics | Total number of electronic cigarette population | |||||||
| Human studies | ||||||||
| Randomized controlled trial (RCT) | ||||||||
| 1 | George et al. [ | Smokers | 74 | N/A | 16 mg/mL | Chronic (1 month) | Some concerns | Switching from conventional cigarette to electronic cigarette improves endothelial function and vascular stiffness marker. |
| 2 | Ikonomidis et al. [ | Smokers | 40 | N/A | 12 mg/mL | Chronic (4 months) | Some concerns | Switching from conventional cigarette to electronic cigarette improves arterial stiffness and oxidative stress. |
| 3 | Ikonomidis et al. [ | Smokers | 70 | Tobacco smokers | 0.12 mg/mL | Chronic (1 month) | High risk | Replacing conventional cigarette with electronic cigarette results in reduced systolic and oxidative stress. |
| Observational; cross-sectional | ||||||||
| 4 | Bricknell et al. [ | Nonsmokers and smokers | 74,013 | N/A | N/A | Observational study | Fair | ENDS (including electronic cigarette) use is associated with stroke. |
| 5 | Fetterman et al. [ | Nonsmokers and smokers | 36 | N/A | N/A | Observational study | Good | Electronic cigarette use is associated with elevated augmentation index (AIx, arterial stiffness marker) and an indication of endothelial dysfunction. |
| 6 | Oliveri et al. [ | Smokers | 144 | Tobacco smokers | N/A | Observational study | Good | Electronic cigarette users show lower levels of biomarkers of exposure (NNK, nicotine, acrolein, and carbon monoxide) and biomarkers of potential harm (platelet activation, oxidative stress, and endothelial function) than cigarette smokers |
| 7 | Podzolkov et al. [ | Nonsmokers and smokers | 2 | N/A | N/A | Observational study | Fair | Smoking traditional and electronic cigarette are related to albuminuria and an increase in the augmentation index (arterial stiffness marker). |
| 8 | Rader et al. [ | Nonsmokers and smokers | 35 | N/A | N/A | Observational study | Poor | Electronic cigarette users show more pronounced impaired coronary microvascular endothelial function than chronic conventional cigarette users. |
| 9 | Sahota et al. [ | Nonsmokers and smokers | 20 | N/A | 4-36 mg/mL | Observational study | Fair | Electronic cigarette users develop more carotid plaque burden than nonsmokers |
| 10 | Vindhyal et al. [ | Nonsmokers and smokers | 401 and 2,240 dual users | N/A | N/A | Observational study | Poor | Electronic cigarette users are associated with an increased risk of myocardial infarction than nonsmokers |
| Animal studies | ||||||||
| 1 | El-Mahdy et al. [ | Animal (mice C57BL/6 J) | 100 | Air | 0, 6, or 24 mg/mL | 60 weeks | Electronic cigarette can induce cardiovascular disease similar to conventional cigarette smoking. The severity of toxicity increases with exposure duration and nicotine content. | |
| 2 | Espinoza-Derout et al. [ | Animals (ApoE–/– mice) | 5/test group | EC without nicotine/saline aerosol | 2.40% | 12 weeks | Electronic cigarette with nicotine induce an abnormal increase in ROS levels and mitochondrial DNA mutations associated with cardiac dysfunction and atherogenesis. | |
| 3 | Kuntic et al. [ | Animal (C57BL/6 and NOX2 null mice) | 151 | Air | 12 mg/ml | 5 days | Electronic cigarette vapor increases vascular, cerebral, and pulmonary oxidative stress via a NOX-2-dependent mechanism. The adverse effect is more pronounced with nicotine than without nicotine. | |
| 4 | Li et al. [ | Animal (mice) | 5-10/test group | Air | 2.40% | 16 weeks | Electronic cigarette increases the level of mitochondrial DNA damage in blood and expression of TLR9 and induces the development of atherosclerosis. | |
| 5 | Olfert et al. [ | Animal (mice C57BL/6 J) | 15 | Air | 18 mg/mL | 32 weeks | Electronic cigarette vapor accelerates arterial stiffness and impairs aortic endothelial function. | |
| 6 | Szostak et al. [ | Animals (ApoE–/– mice) | 309 (10-16/test group) | Air | 4% | 24 weeks | Electronic cigarette vapor shows small or completely absent effects on systolic and diastolic functions of the heart, atherosclerotic progression, altered lipid profiles, and alteration of the heart ventricle and aorta transcriptomes compare to 3R4F conventional cigarette smoke. | |
Notes: (∗) The SYRCLE's RoB for animal intervention does not provide overall risk of bias.
Risk of bias assessment of 3 randomized controlled trial studies using RoB 2.
| Criteria | George et al. [ | Ikonomidis et al. [ | Ikonomidis et al. [ |
|---|---|---|---|
| Bias arising from the randomization process | Some concerns | Some concerns | High risk |
| Bias due to deviations from intended interventions | Some concerns | Some concerns | Low risk |
| Bias due to missing outcome data | Low risk | Low risk | Low risk |
| Bias in measurement of the outcome | Low risk | Low risk | Low risk |
| Bias in selection of the reported result | Low risk | Some concerns | Some concerns |
| Overall risk of bias | Some concerns | Some concerns | High risk |
Risk of bias (quality) assessment of 7 observational (cross-sectional) studies using NIH Quality Assessment.
| Criteria | Bricknell et al. [ | Fetterman et al. [ | Oliveri et al. [ | Podzolkov et al. [ | Rader et al. [ | Sahota et al. [ | Vindhyal et al. [ |
|---|---|---|---|---|---|---|---|
| Was the research question or objective in this paper clearly stated? | Yes | Yes | Yes | Yes | No | Yes | Yes |
| Was the study population clearly specified and defined? | Yes | Yes | Yes | Yes | No | Yes | Yes |
| Was the participation rate of eligible persons at least 50%? | Yes | Yes | No | Yes | Not reported | Yes | Not reported |
| Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | Yes | Yes | Yes | Yes | Not reported | Yes | Yes |
| Was a sample size justification, power description, or variance and effect estimates provided? | No | No | Yes | No | No | No | No |
| For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | No | No | No | No | No | No | No |
| Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | No | No | No | No | No | No | No |
| For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |
| Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | No | No | No | No | No | No | No |
| Was the exposure(s) assessed more than once over time? | No | No | No | No | No | No | No |
| Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | No | Yes | Yes | Yes | Yes | Yes | No |
| Were the outcome assessors blinded to the exposure status of participants? | Not applicable | Yes | Yes | Yes | Not reported | Not reported | Not applicable |
| Was loss to follow-up after baseline 20% or less? | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |
| Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | Yes | Yes | Yes | Not applicable | Not applicable | Not applicable | Yes |
| Overall quality rating | Fair | Good | Good | Fair | Poor | Fair | Poor |
Risk of bias assessment of 6 animal studies using SYRCLE's RoB.
| Criteria | El-Mahdy et al. [ | Espinoza-Derout et al. [ | Kuntic et al. [ | Li et al. [ | Olfert et al. [ | Szostak et al. [ |
|---|---|---|---|---|---|---|
| Random group allocation (selection bias) | Unclear | No | No | No | Unclear | Unclear |
| Groups similar at baseline (selection bias) | Yes | Unclear | Unclear | Unclear | Yes | Yes |
| Blinded group allocation (selection bias) | No | No | No | No | No | No |
| Random housing (performance bias) | No | No | No | No | No | No |
| Blinded intervention (performance bias) | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear |
| Random outcome assessment (detection bias) | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear |
| Blinded outcome assessment (detection bias) | No | No | No | No | No | No |
| Reporting of drop-outs (attrition bias) | Yes | Yes | Yes | Yes | Yes | Yes |
| Selective outcome reporting | Yes | Yes | Yes | Yes | Yes | Yes |
| Other biases | Yes | Yes | Yes | Yes | Yes | Unclear |
Notes: In the SYRCLE's RoB, ‘Yes' indicates low risk of bias; No indicates high risk of bias; ‘Unclear' indicates unclear risk of bias.